Phase I/II Study of CEND-1 In Combination With Neoadjuvant FOLFIRINOX in Patients with Solid Tumors, including Pancreatic Cancer (CENDIFOX)
Summary
The purpose of this phase I/II study is to evaluate the safety and efficacy of CEND-1 in combination with FOLFIRINOX with or without Panitumumab in patients with solid tumors, including pancreatic cancer.
General Information
NCT#: NCT05121038
Study ID: IIT-2021-CENDIFOX
Trial Phase: Phase I/II
Trial Sponsor: Anup Kasi
Therapies Used in This Trial: Panitumumab, FOLFIRINOX, CEND-1